

Issues Y Topics ~ Subscribe Now Log In

CME ~ Multimedia V Info V

Derm Atlas Y

















Published online November 15, 2023

Matthew F. Helm MD^a, Peter A. Khoury BS^b, Haig Pakchanian BS^c, Rahul Raiker BS^d,

Steven Maczuga MS^a, Galen T. Foulke MD^a

Search page

Search...

Q

^aDepartment of Dermatology, Penn State Health, Hershey, PA

^bCollege of Osteopathic Medicine, Kansas City University, Joplin, MO

°School of Medicine and Health Science, George Washington University, Washington, DC

^dSchool of Medicine, West Virginia University, Morgantown, WV

Advertisement

Popular

ABSTRACT

Background: Herpes zoster increases the risk for stroke and myocardial infarction. Zoster vaccination's impact on this risk is understudied. This retrospective work sought to determine if prophylactic herpes zoster vaccination may reduce the risk of stroke, myocardial infarction, and/or mortality.

Methods: A cohort analysis utilized TriNetX, a national, federated database. In one analysis, patients who received 2 doses of recombinant zoster vaccine (RZV) were compared to adults without RZV. A 1:1 propensity-score match analysis was conducted to adjust for demographics and comorbidities in calculating adjusted relative risks (aRR) with 95% confidence intervals. Firsttime incidences for myocardial infarction, stroke, and mortality were assessed after 3 years. A subgroup analysis between RZV and zoster vaccine live (ZVL) was also assessed.

Results: Matched cohorts of 7,657 patients revealed that adults who received 2 doses of RZV were at lower risk of MI (aRR [95% CI]) = (0.73 [0.55, 0.96]) and mortality (0.7 [0.57, 0.88]) while having similar risk for stroke (0.97 [0.75, 1.26]). Further subgroup analysis also revealed a reduced risk of 3-year mortality when compared to the ZVL cohort (0.84 [0.74, 0.95]). Sample size and comorbidities included in the analysis were limited by using a large database.

2023 JDD Welcome Kit December 18, 2023

PRP and Microneedling: What's the Hype? December 7, 2023

Author Spotlight: Jayme Heim MSN FNP-P

er 27,

Privacy & Cookies Policy



Home Issues Y Topics Y Subscribe Now Log In

CME Y Multimedia Y Info Y Derm Atlas Y

Inetime. Herpes zoster (sningles) is a reactivation of latent varicella-zoster virus (VZV), which is responsible for varicella (chickenpox). Zoster is often seen in individuals over 50 or with compromised immune systems. Reactivation of VZV manifests as painful rash and potential medical complications such as post-herpetic neuralgia (PHN) and vision loss due to herpes zoster ophthalmicus (HZO) may occur.

Age and immunosuppression can increase the risk of herpes zoster. In the US, the number of Americans above the age of 60 increased by 34% between 2009 and 2019, and the population aged 65 and older numbered 54.1 million in 2019 (16% of the total population).⁵

people 60 years and older is about 1 case per 100 annually.⁷ A high incidence of herpes zoster has also been reported in immunocompromised or immunosuppressed patients of any age.^{8,9}

Studies report that herpes zoster increases the risk of cardiovascular and cerebrovascular events, including stroke and myocardial infarction. 10-12 Herpes zoster vaccination's impact on these events is understudied. Given the growing population at risk for herpes zoster reactivation and the reported relationship between herpes zoster and other health issues, prevention is important to boost VZV-specific immunity.

Dermatology
Roundup: AAD
Decries
Physician Fee
Schedule Cuts
November 15, 2023

Advertisement

1 2 3 4 5 > >>





Home Issues ' Topics ' CME ' Multimedia ' Info ' Derm Atlas ' Subscribe Now Log In



Oats in Skincare

Oncoderm

Pigmentary Disorders

Psoriasis

Rosacea

Skin Cancer

Skin of Color

Webinars



Home Issues ' Topics ' CME ' Multimedia ' Info ' Derm Atlas ' Subscribe Now Log In

Store



OITE	
COVID-19	
Featured Articles	
Issue Highlights	
Oats in Skincare	
Oncoderm	
Pigmentary Disorders	
Psoriasis	
Rosacea	
Skin Cancer	
Skin of Color	
Webinars	

Journal of Drugs in Dermatology		
About Us		
Contact Us		
Contact Sales		
Editorial Board		
eJDD		
Institutional, Library, & Corporate Subs	criptions	
Log In		
Open Access		
Permissions Request		
Podcast Sponsorship		
Subscription Info		

Home Issues \(^{\sigma}\) Topics \(^{\sigma}\) CME \(^{\sigma}\) Multimedia \(^{\sigma}\) Info \(^{\sigma}\) Derm Atlas \(^{\sigma}\) Subscribe Now Log In \(^{\sigma}_{-1}\)

of in ©